| 1 |
32495214 | The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells. | 2020 Jun 3 |
4 |
| 2 |
31416167 | Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. | 2019 Aug 14 |
1 |
| 3 |
31484985 | Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients. | 2019 Sep 4 |
1 |
| 4 |
29214842 | Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. | 2018 Mar |
1 |
| 5 |
28377489 | Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers. | 2017 Jul |
1 |
| 6 |
28552047 | T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial. | 2017 |
2 |
| 7 |
28648785 | LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. | 2017 Oct 25 |
1 |
| 8 |
28894364 | EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer. | 2017 |
1 |
| 9 |
25756468 | Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine. | 2016 Mar-Apr |
1 |
| 10 |
26318092 | Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. | 2016 Jan |
3 |
| 11 |
26938945 | Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. | 2016 Apr |
3 |
| 12 |
27274311 | Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. | 2016 |
2 |
| 13 |
25398397 | T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. | 2015 Jan |
1 |
| 14 |
25790739 | [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. | 2015 Apr |
1 |
| 15 |
25865453 | Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. | 2015 May |
2 |
| 16 |
26031461 | Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. | 2015 |
2 |
| 17 |
26240273 | Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. | 2015 Dec 15 |
1 |
| 18 |
26254411 | T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. | 2015 Sep |
1 |
| 19 |
25191794 | Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. | 2014 Oct 9 |
1 |
| 20 |
25339854 | Enhanced anticancer activity of DM1-loaded star-shaped folate-core PLA-TPGS nanoparticles. | 2014 |
3 |
| 21 |
23402224 | Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. | 2013 Apr |
3 |
| 22 |
22942906 | The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. | 2012 Sep |
1 |
| 23 |
23247898 | [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. | 2012 Dec |
2 |
| 24 |
24451727 | Trastuzumab Emtansine (T-DM1): Hitching a Ride on a Therapeutic Antibody. | 2012 |
1 |
| 25 |
20730488 | Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. | 2011 Jul |
1 |
| 26 |
21391620 | Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. | 2011 Apr 20 |
2 |
| 27 |
21481526 | Antibody-DM1 conjugates as cancer therapeutics. | 2011 Aug 28 |
1 |
| 28 |
21506905 | Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. | 2011 Jun |
2 |